Authors: Lovett, BD Strumberg, D Blair, IA Pang, SK Burden, DA Megonigal, MD Rappaport, EF Rebbeck, TR Osheroff, N Pommier, YG Felix, CA

Citation: Bd. Lovett et al., Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints, BIOCHEM, 40(5), 2001, pp. 1159-1170

Authors: Burden, DA Froelich-Ammon, SJ Osheroff, N

Citation: Da. Burden et al., Topoisomerase II-mediated cleavage of plasmid DNA, METH MOL B, 95, 2000, pp. 283-289

Authors: Burden, DA Osheroff, N

Citation: Da. Burden et N. Osheroff, In vitro evolution of preferred topoisomerase II DNA cleavage sites, J BIOL CHEM, 274(8), 1999, pp. 5227-5235

Authors: Byl, JAW Fortune, JM Burden, DA Nitiss, JL Utsugi, T Yamada, Y Osheroff, N

Citation: Jaw. Byl et al., DNA topoisomerases as targets for the anticancer drug TAS-103: Primary cellular target and DNA cleavage enhancement, BIOCHEM, 38(47), 1999, pp. 15573-15579

Authors: Kingma, PS Burden, DA Osheroff, N

Citation: Ps. Kingma et al., Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance, BIOCHEM, 38(12), 1999, pp. 3457-3461